Over eight lakh stroke patients in north India are being prescribed neuroprotective drugs which are not recommended by clinical practice guidelines set by the world bodies, an AIIMS study has revealed.
Citicoline, Piracetam, and Edaravone are the three drugs being prescribed to the stroke patients over the years in spite of the directions from the medical bodies against prescribing them as they have been found non-effective in stroke patients.
The two-year study of the medicines being prescribed to the stroke patients also revealed that medicine such as blood pressure lowering agents - statins, and anti-platelet agents which were found being actually effective were not being administered to patients.
A report from Indian Council of Medical Research (ICMR) indicated that in 2004 there were approximately 9,30,985 cases of stroke in the country with 6,39,455 deaths.
The National Commission on Macroeconomics and Health, India, recently estimated 1.67 million stroke cases in the country by 2015.
"Both specialist and private hospitals are associated with higher prescription of "ineffective neuroprotective" drugs in both poor and rich patients," the AIIMS study's report exclusively given to the IANS.
Kameshwar Prasad, head of Neurology at AIIMS and under whom the research was conducted, said, "The reasons are yet to be studied but the speculative reasons are that often the doctors miss particular medicines due to the constant pressure on them and also they forget about it."
He said the other speculative reason behind the issue was that even the patients are not aware of the effective medicines, which is actually very necessary.
Prasad also said though the study only revealed about north India, the situation may be much more worse in other parts of India, as they were out of the direct purview of the union health ministry.
"Once we get to know about the total spending on the medicines incurred by the health ministry only then we can get to know how much of money is spent on buying the ineffective drugs in the country," he told IANS.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
